Ovid Therapeutics
Develops targeted small molecules for neurological disorders involving neuronal hyperexcitability.
$2.81
After-hours close0.00 (0.00%)
At close$2.81(−4.10%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 56.29%105.07M sharesInsiders 2.27%4.24M sharesOther 41.44%77.33M shares
Shares outstanding 186.64M · Float 154.02M · 82.5% free float
Institutions13F, as of Mar 31, 2026
109 holders · 105.07M shares · 29 new positions · 63 increased · 19 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10.71M | 5.74% | 0 | May 15, 2026 |
| Janus Henderson Group PLC | 10.71M | 5.74% | +10.71Mnew | May 18, 2026 |
| Affinity Asset Advisors, LLC | 10.64M | 5.70% | +3.49M | May 14, 2026 |
| Eventide Asset Management, LLC | 9.92M | 5.31% | +5.63M | May 15, 2026 |
| Adage Capital Partners GP, L.L.C. | 6.16M | 3.30% | +2.67M | May 15, 2026 |
| Balyasny Asset Management L.P. | 5.53M | 2.96% | +5.21M | May 15, 2026 |
| Vanguard Capital Management LLC | 5.26M | 2.82% | +5.26Mnew | May 15, 2026 |
| Adar1 Capital Management, LLC | 4.54M | 2.43% | +259.1K | May 18, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | 12.30% | 8.78M | 13G | Dec 9, 2025 ↗ |
| Janus Henderson Group PLC | 9.99% | 7.11M | 13G | Dec 8, 2025 ↗ |
| Sirenia Capital Management LP | 9.90% | 18.03M | 13G | May 15, 2026 ↗ |
| RA Capital Management, L.P. | 9.90% | 13.26M | 13G | Dec 18, 2025 ↗ |
| Affinity Asset Advisors, LLC | 9.10% | 15.64M | 13G | May 14, 2026 ↗ |
| Eventide Asset Management, LLC | 7.30% | 12.77M | 13G | May 15, 2026 ↗ |
| ADAR1 Capital Management, LLC | 6.90% | 9.28M | 13G | Feb 17, 2026 ↗ |
| Federated Hermes, Inc. | 5.94% | 7.74M | 13G | Jan 8, 2026 ↗ |
| BlackRock, Inc. | 5.80% | 10.82M | 13G | Jul 29, 2026 ↗ |
| Balyasny Asset Management L.P. | 5.33% | 7.03M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 10 percent owner | 7.00M | 3.75% | Dec 9, 2025 |
| Jeremy M. Levin | director, officer: Executive Chairman | 3.74M | 2.00% | Mar 25, 2026 |
| Stelios Papadopoulos | director | 217.6K | 0.12% | Apr 9, 2026 |
| Jeffrey A. Rona | officer: CBFO | 156.3K | 0.08% | Mar 2, 2026 |
| Margaret A. Alexander | director, officer: President and CEO | 61.8K | 0.03% | Mar 2, 2026 |
| Charles Ross Carter | officer: Chief Financial Officer | 44.4K | 0.02% | Jul 8, 2026 |
| Kevin Joseph Fitzgerald | director | 17.6K | 0.01% | Apr 9, 2026 |
| Bart Friedman | director | 8.8K | 0.00% | Apr 9, 2026 |
1 ten-percent owner holds 7.00M shares by Form 4 — the 13D/G table above shows that stake, the figure above counts officers and directors only · 6 people have not refiled in the last 18 months (5.12M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Feb 23, 2026 | Jeffrey A. Ronaofficer: CBFO | Sale | 8,541 | $1.45 | 88,188 |
| Feb 23, 2026 | Margaret A. Alexanderdirector, officer: President and CEO | Sale | 11,656 | $1.45 | 61,750 |
| Dec 11, 2025 | Jeremy M. Levindirector, officer: CEO | Purchase · 3 lots | 82,904 | $1.40 | 82,904 |
CongressHouse and Senate disclosures
Not reported.